Bio-Rad Receives FDA License for Two New Hepatitis B Tests
HERCULES, Calif. -- Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that two of its test kits used for the screening and confirmation of the Hepatitis B virus have been approved by the Food and Drug Administration (FDA).
Bio-Rad's Genetic Systems HBsAg EIA 3.0 and HBsAg Confirmatory Assay 3.0 also received medical device licenses from the Medical Devices Bureau at Health Canada. These tests replace the company's existing Hepatitis B kits. They are more sensitive, easier to use, and are the only Hepatitis B tests on the market approved for use on cadaveric samples. They will be available throughout the U.S. and Canada within weeks.
"We are pleased to be able to make these much-needed tests available to our customers in the U.S. and Canada," said John Goetz, vice president of Bio-Rad's Clinical Diagnostics Group. "These licensing approvals come at a critical time as public health concerns over the safety of the blood supply increase."
Hepatitis B is the most common liver infection in the world. It affects an estimated 400 million people and is the leading cause of liver cancer. The World Health Organization estimates that the virus leads to more than 1 million deaths every year. It is transmitted through blood and other bodily fluids through direct contact with infected blood, unprotected sex, drug use, and is also passed from infected mothers to their offspring during birth. Hepatitis B has become a major public health problem worldwide, with significant transmission of the virus occurring through the use of contaminated donor blood and plasma. Effective screening can aid in the prevention of the virus.
Bio-Rad's new Hepatitis B test, the HBsAg EIA 3.0, is licensed for blood screening and for diagnostic testing of human serum, plasma and cadaveric serum specimens. The HBsAg Confirmatory Assay 3.0 is approved for confirmatory use on reactive specimens. These tests are currently the most sensitive Hepatitis B tests available in the U.S. Bio-Rad also produces a variety of other diagnostic test kits used for HIV, blood viruses, and autoimmune diseases, as well as tests for the detection of genetic disorders and food-borne pathogens like listeria, salmonella and BSE (bovine spongiform encephalopathy or mad cow disease).
Source: Bio-Rad Laboratories, Inc.
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
